Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology
ILMNThe FDA-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test, helping to advance adoption in the US healthcare system SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that reimbursement has been granted for...
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery
ILMNThe Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug...
Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026
ILMNSAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2025 following the close of market on Thursday, February 5, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob...
Illumina Appoints Dr. Eric Green as Chief Medical Officer
ILMNVeteran genomics leader joins Illumina to advance global medical strategy Illumina chief commercial officer to depart for role as a life science tools company CEO SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ: ILMN) announced the appointment of Eric D. Green, M.D.,...
Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis
ILMNIntegrated software, AI-driven analytics, and frictionless workflows enable customers to harness the full power of biological insights SAN DIEGO, Jan. 6, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the release of Illumina Connected Multiomics, a powerful cloud-based...
Illumina To Webcast Upcoming Investor Conference
ILMNSAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conference 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 The presentation...
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually
ILMNPartnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO and MENLO PARK, Calif., Dec. 11, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and MyOme, a...
Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
ILMN(NASDAQ:ILMN) Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, customers commend scale, high consistency, and easy sample to insights workflow Launch follows...
Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
ILMN(NASDAQ:ILMN) Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, customers commend scale, high consistency, and easy sample to insights workflow Launch follows...
Global Minimal Residual Disease Testing Market Gearing Up for Outstanding Expansion at a CAGR of ~11% by 2032 | DelveInsight
ILMNThe demand for minimal residual disease testing is increasing mainly due to the higher prevalence of solid tumors and blood cancers like leukemia, multiple myeloma, and lymphoma. Continuous advances in molecular diagnostics have greatly improved MRD detection accuracy, and active product...
Breaking Down Illumina: 11 Analysts Share Their Views
ILMNCanaccord Genuity Maintains Hold on Illumina, Raises Price Target to $99
ILMNIllumina Unveils PromoterAI, New AI Algorithm That Accurately Deciphers Pathogenic Regulatory Genetic Variants In Noncoding Regions Of Human Genome
ILMNIllumina Expands Clinical Oncology Portfolio, Unlocking Next New Solutions To Advance Precision Oncology And Improve Standard Of Care
ILMNCathie Wood Reiterates 'Profound' AI Application In Healthcare As Researchers Discover 'Cancer Survival Outcomes' By Facial Photograph Analysis: Here Are The Stocks That Could Benefit
ILMNCathie Wood underscored the application of AI in the healthcare sector by sharing new research by Mass General Brigham.
What 15 Analyst Ratings Have To Say About Illumina
ILMNStephens & Co. Reiterates Overweight on Illumina, Maintains $105 Price Target
ILMNPiper Sandler Maintains Overweight on Illumina, Lowers Price Target to $185
ILMNIllumina Analysts Lower Their Forecasts After Q1 Results
ILMNMorgan Stanley Maintains Equal-Weight on Illumina, Lowers Price Target to $100
ILMNCanaccord Genuity Maintains Hold on Illumina, Lowers Price Target to $87
ILMNGuggenheim Maintains Buy on Illumina, Lowers Price Target to $114
ILMNIllumina Lowers FY2025 Adj EPS Guidance from $4.50 to $4.20-$4.30 vs $4.45 Est; Core Illumina revenue to decline between (1%) and (3%) on a constant currency basis YoY
ILMNIllumina Q1 Adj. EPS $0.97 Beats $0.94 Estimate, Sales $1.04B Beat $1.03B Estimate
ILMNIllumina And Ovation.io Launching GLP-1 Dataset To Accelerate New Therapy Development
ILMNAssessing Illumina: Insights From 16 Financial Analysts
ILMNCanaccord Genuity Maintains Hold on Illumina, Lowers Price Target to $92
ILMNRep. Thomas Kean Has Bought Up to $45K Worth Of Illumina Stock: Here's What You Should Know
ILMNBarclays Maintains Underweight on Illumina, Lowers Price Target to $77
ILMNRBC Capital Maintains Outperform on Illumina, Lowers Price Target to $112
ILMNDeep Dive Into Illumina Stock: Analyst Perspectives (14 Ratings)
ILMNCitigroup Maintains Neutral on Illumina, Lowers Price Target to $85
ILMNHow Do Investors Really Feel About Illumina?
ILMNHere's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today
ILMNIllumina Elects Dr. Scott Gottlieb As Non-Executive Chair
ILMNRBC Capital Maintains Outperform on Illumina, Lowers Price Target to $128
ILMNDiagnostic Kit Maker Illumina To Cut $100 Million In Costs, Lowers 2025 Profit Outlook Amid China Trade Restrictions
ILMNIllumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for high-single-digit growth by 2027.
Stephens & Co. Reiterates Overweight on Illumina, Maintains $156 Price Target
ILMN'Illumina To Cut $100M In Costs, Lowers Guidance Because Of China Sales Ban; Beijing Banned Imports Of Illumina's Gene-Sequencing Machines In Response To U.S. Tariffs; Cuts 2025 Adjusted Earnings Guidance To $4.50 A Share' - WSJ
ILMNIllumina Named To Dow Jones Best-In-Class World And North America Indices For Sixth Year
ILMNDemystifying Illumina: Insights From 11 Analyst Reviews
ILMNBaird Maintains Neutral on Illumina, Lowers Price Target to $90
ILMNCitigroup Maintains Neutral on Illumina, Lowers Price Target to $90
ILMNUS Firm Illumina Faces Setback as China Blocks Imports Amid Escalating Trade War
ILMNChina banned imports of Illumina's gene sequencers as new U.S. tariffs took effect, cutting its market access while Chinese rivals gain ground in the biotech sector.
Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today
ILMN$1000 Invested In Illumina 20 Years Ago Would Be Worth This Much Today
ILMNIllumina Unveils Largest Omics Solutions Portfolio Including Genomics, Spatial, Single Cell, CRISPR Technologies; Introduces Multimodal Data Analysis Platform
ILMNIllumina Collaborates With Broad Clinical Labs To Rapidly Streamline And Scale Single-Cell Projects With Cutting-Edge Tools And Workflows
ILMNCarl Icahn Cuts Shared Share Stake In Illumina Inc. By 90.7% To 40,000 Shares
ILMNIllumina Raises Q4 Revenue Outlook To $1.10 Billion, Exceeding Street Expectations; Sees Solid Margins
ILMNIllumina raises Q4 and FY24 revenue outlook, expects solid margins, with projected 2024 EPS between $4.12 and $4.14.
